Newronika Announces First Participant Implanted in ADVENT Pivotal Study
Newronika Announces First Participant Implanted in ADVENT Pivotal Study
Newronika
Private
Newronika is a Milan-based medtech company pioneering adaptive deep brain stimulation (aDBS) therapy. Their αDBS platform received CE Mark certification in July 2026, advancing adaptive DBS as a new standard of care for Parkinson's disease and other movement disorders.
Company Info
Sector:Medical Devices / Neurotechnology
Headquarters:Milan, Italy
Founded:2008
Website:newronika.com/
Funding Round:Series C
Total Funding:See company disclosures
Funding & Investor Relations
IPO Outlook / Plans
Pre-IPO; no announced timeline
Upcoming Milestones & Key Dates
2026-Q4
Commercial
EU commercial launch of αDBS platform
2026-Q4
Regulatory
FDA IDE filing
Clinical Development Pipeline
αDBS System
Target: Closed-loop neural stimulationαDBS System
Target: Closed-loop neural stimulationRecent News
Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care
/PRNewswire/ -- Newronika S.p.A., the Milan-based medtech company redefining deep brain stimulation therapy, has received CE Mark certification for the latest...
Leadership Team
Dr. Lorenzo Rossi
CEO & Co-Founder
TBD
Chief Medical Officer
TBD
VP Engineering